Emcure launches generic breast cancer drug 40% cheaper than innovator's

Pune-based Emcure Pharmaceuticals, which launched a generic version of Eisai Pharma’s innovator breast cancer drug Eribulin (brand name Halaven), aims to expand the market for the drug by 30 per cent. Emcure’s drug that would be sold under the brand name Eribilin is 40 per cent cheaper compared to the innovator drug.
 
Globally, this is the first generic drug for the molecule Eribulin, which is sold under the brand name Halaven. Emcure plans to capture 25 per cent of the market for the drug as well as expand the market through this cheaper alternative to the innovator drug.